Regenxbio (RGNX) Stock
Gene therapy developer using AAV platform for inherited conditions. Here's the price, business snapshot, and what's worth knowing about Regenxbio in July 2026.
Regenxbio Inc (RGNX) is a clinical‑stage biotechnology company focused on developing gene therapies using its proprietary NAV AAV platform. Investors should know it centres on designing and delivering adeno‑associated virus (AAV) vectors to address a range of inherited and acquired conditions, and it supports programmes through partnerships and licensing. With a market capitalisation of approximately $661.23M, Regenxbio can offer upside tied to positive clinical readouts or successful collaborations, but it remains subject to the typical biotech risks: long development timelines, high R&D spend, binary trial results and regulatory uncertainty. The share price can be volatile and funding or dilution remains possible. This overview is general educational information and not personalised investment advice; Regenxbio may be suitable only for investors who understand and accept the high-risk, high-uncertainty nature of clinical-stage biotech investments.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying REGENXBIO’s stock with a target price of $32.77, indicating strong growth potential.
Financial Health
REGENXBIO is performing well financially with strong revenue and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring RGNX
Investment Opportunities in RNA Therapeutics Explained
Eli Lilly's $2.4 billion acquisition of Orna Therapeutics signals a major bet on circular RNA and in vivo cell engineering. This theme focuses on the broader ecosystem of companies developing the next-generation platforms and delivery technologies essential for advancing genetic medicine.
Published: 10 February 2026
Explore BasketRNA Stocks (M&A Targets) Could See Premium Valuations
Novartis's $12 billion acquisition of Avidity Biosciences underscores the high value of RNA-based treatments for rare diseases. This deal could spark a wave of similar acquisitions, creating opportunities for other biotech companies with innovative RNA platforms.
Published: 27 October 2025
Explore BasketGene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: 30 July 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: 29 July 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: 25 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
NAV AAV Platform
A proprietary AAV platform underpins many programmes and collaborations — it may enable broad applications, though development is costly and outcomes uncertain.
Clinical Milestones
Trial readouts and regulatory steps tend to drive share movements; positive data can increase value, while setbacks are common and may be swift.
Partnerships Matter
Collaborations can provide funding and expertise and help de‑risk programmes, but commercial returns depend on successful development and approvals.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
